Epidyolex receives marketing approval by European Commission

Further to our recent news article here, we can confirm that CBD based drug Epidyolex has received marketing approval by the EU commission.

Approval for the drug has been granted for in Lennox Gastaut & Dravet Syndromes in patients over two years old who are already prescribed Clobazam (Frisium). The marketing approval will apply to all EU member states, including Ireland.

Meta-Analysis Study points to higher success rate for early surgical intervention

A meta-analysis of studies regarding epilepsy surgery has concluded that the earlier surgical intervention takes place, the more chance a person has of becoming seizure- free.

The analysis was conducted by researchers from the Sahlgrenska Academy of the University of Gothenburg in conjunction with the Swedish Council for Assessment of Health Technology.

Children with Epilepsy due to Genetic Abnormality respond better to Ketogenic Diet- American Research finds

New research from the Ann & Robert H Lurie Children’s Hospital of Chicago has found that young children with epilepsy caused by genetic abnormality had a better response to the ketogenic diet compared to children with other types of epilepsy.

The ketogenic diet is a low carbohydrate, high fat diet that is used to treat epilepsy which has not responded to other treatments. More information on this can be found here.